Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2013 | 07:59pm CET

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

   By Saabira Chaudhuri 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
03:06p ELI LILLY AND : Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis a..
02/27 ELI LILLY AND : Barriers to Integrated Care and How to Overcome Them
02/24 ELI LILLY AND : Trademark Application for "TOLIENT" Filed
02/24 ELI LILLY AND : New Enzymes and Coenzymes Data Have Been Reported by Researchers..
02/24 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/24 ELI LILLY AND : New Chronic Kidney Disease Findings Reported from E.B. Wang and ..
02/24 ELI LILLY AND : Additional results from pivotal RA-BEAM study published in New E..
02/22 ENDOCYTE : Appoints Michael T. Andriole as Chief Financial Officer
02/22 INSIDER TRADING ACTIVITY ELI LILLY A : LLY) – Major Shareholder Sold 230,0..
02/21 ELI LILLY AND : LILLY ELI & CO Management's Discussion and Analysis of Results o..
More news
Sector news : Pharmaceuticals - NEC
06:30p EXCLUSIVE : Merus Labs hires Rothschild to explore options - sources
04:18p Valeant predicts tough 2017 with revenue to decline
08:35aDJASTRAZENECA : FDA OKs Once-Daily Qtern for Type-2 Diabetes
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:41a GE Breaks Up
11:18a FDA accepts Eagle Pharma's NDA for liquid version of Lilly's Alimta, action d..
02/27 Biotechs scorching today, IBB up 3%
02/24 Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
02/24 4 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Febr..
Financials ($)
Sales 2017 22 136 M
EBIT 2017 5 494 M
Net income 2017 3 876 M
Debt 2017 4 117 M
Yield 2017 2,57%
P/E ratio 2017 25,43
P/E ratio 2018 21,19
EV / Sales 2017 4,33x
EV / Sales 2018 4,23x
Capitalization 91 644 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 86,5 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Aarti Shah Chief Information Officer & Senior Vice President
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO12.67%91 644
JOHNSON & JOHNSON6.53%332 993
ROCHE HOLDING LTD.5.42%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG4.72%203 039
MERCK & CO., INC.12.38%181 558
More Results